Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nokia Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Nokia Corp trades at $9.27 (market cap $54.48B). The key difference: Nokia Corp is far larger — about 55.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Nokia Corp pays a 1.74% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nokia Corp for 65 Days on average.
| MRVI | NOK | |
|---|---|---|
Market Cap | $977.37M | $54.48B |
Volume | 2,742,564 | 85,996,980 |
Sector | Health | Technology |
52-Week High | $9.00 | $16.83 |
52-Week Low | $2.83 | $5.55 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $1.08B | $52.50B |
Dividend Yield | — | 1.74% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Nokia (NOK) trades at $9.86, down 0.4% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships in AI, satellite communications, and network automation, including an expanded collaboration with Microsoft announced on September 17, 2026.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (59.6%) and a consensus price target of $17.50, implying significant upside. Key opportunities include growth in AI and cloud infrastructure demand, while risks involve competitive pressures and inconsistent earnings performance. Cash flow volatility remains a concern, with net cash flow negative in 2025 and 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →